Nice move Licemonkey, but if you down get tested by those occasionally false positive "Made in China" that Biden was so proud of sending out, how will they get the numbers up to prove it's real?
To be clear, substack.com is an effectively open site where people can post/write anything. Nothing in this link is cited with only two external links (that I could see) that go to shit or just a root domain.
My elderly boomer started taking this prophylactically in late 2020. He stopped for awhile after he got vaxxed but then he started up again because clearly that shit was not working. He takes about 18 mg once weekly. The horse stuff. I tried to make him isolate for a year or so but now he justs runs around as he pleases. I do not want him to get this shit. Not omicron or anything else. He’s too old. He’s like Joe Biden old.
So he still has not gotten covid. He has been exposed alot by less cautious family members. I still can’t believe it. I hope Im not jinxing it by writing this comment. I think it might be the ivermectin. It hasn’t really caused any problems except for mild diarrhea but that problem was solved with some probiotic yogurt. Im glad he’s not dead. Usually.
Where's the study? It's not linked in the article, but rather screen caps from the study. Paywall or not, it would be preferred to link the study in there so that it could be shared with people who would deflect the conversation towards the author not being certified as fake news or some other retarded shit.
"Background: We have previously demonstrated that ivermectin used as prophylaxis for COVID-19, irrespective of the regularity or the level of monitoring, in a strictly controlled city-wide program in Southern Brazil (Itajaí, SC, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin showed an impact on the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect. Materials and methods: This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2mg/kg/day for two consecutive days, every 15 days. Data was gathered over a 150-day period. Regularity definitions were as follows: regular users had 180mg or more of ivermectin; irregular users had up to 60mg, in total, throughout the period of the program. Comparisons were made between non-users (subjects who did not use ivermectin), regular and irregular users from the city of Itajaí after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and risk of dying from COVID-19. The COVID-19 database was used, propensity score matching (PSM) was evened for intervals of age and comorbidities for hospitalization and mortality rates, and then adjusted for remaining variables (doubly adjusted). Risk of dying from COVID-19 was determined by the number of COVID-19 deaths in a certain population exposed to COVID-19. Results: Among 223,128 subjects analyzed from the city of Itajaí, 159,560 had 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8% of users) used irregularly (up to 60mg) and 8,325 (7.3%) used regularly (more than 180mg). The remaining 71,548 participants (62.9%) used intermediate dioses (between 60mg and 180mg) and were not included for analysis. A total of COVID-19 infection rate was 49% lower for regular users (3.40% rate) than non-users (6.64% rate) [risk rate (RR), 0.51; 95% confidence interval (95%CI), 0.45–0.58; p<0.0001], and 25% lower than irregular users (4.54% rate) (RR, 0.75; 95%CI, 0.66–0.85; p<0.0001]. The infection rate was 32% lower for irregular users than non-users (RR, 0.68; 95%CI, 0.64–0.73; p<0.0001). Among COVID-19 participants, regular users were older and had higher a prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, and between regular users and irregular users, and 1,542 subjects between non-users and irregular users. Hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p<0.0001 for both), and by 29% among irregular users compared to non-users (RR, 0.781; 95%CI, 0.49–1.05; p=0.099). Mortality rate was 92% lower in regular users than non-users (RR, 0.08; 95%CI, 0.02–0.35; p=0.0008) and 84% lower than irregular users (RR, 0.16; 95%CI, 0.04–0.71; p=0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR, 06.7; 95%CI, 0.40–0.99; p=0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR, 0.14; 95%CI, 0.03–0.57; p=0.006), and 72% lower than irregular users (RR, 0.28; 95%CI, 0.07–1.18; p=0.083), while irregular users had a 51% reduction compared to non-users (RR, 0.49; 95%CI, 0.32–0.76; p=0.001). Conclusion: Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin in a PSM comparison of a strictly controlled population. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19. NOTE: This is the new version of the manuscript that analyzed the efficacy of ivermectin according to the regularity of its use. Due to the substantial changes, a new page has been created. ResearchGate Logo Discover the world's research
20+ million members 135+ million publications 700k+ research projects Join for free
Public Full-text 1
Content uploaded by Cadegiani Flávio Author content Content may be subject to copyright. 1 Regular use of ivermectin as prophylaxis for COVID-19 led up to 92% reduction in COVID-19 mortality rate in a dose-response manner: results of a prospective observational study of a strictly controlled population of 88,012 subjects among 223,128 participants. Lucy Kerr, MD, ARDMS1, Fernando Baldi, PhD2, Raysildo Barbosa Lôbo, PhD3, Washington Luiz Olivato Assagra4, Fernando Carlos Proença5, Jennifer A. Hibberd, DDS, DPD, MRCDC6, Juan J Chamie-Quintero7, Pierre Kory, MD, MPA8, Flavio A. Cadegiani, MD, MSc, PhD8,9 1Instituto Kerr, São Paulo, Brazil 2Department of Animal Sciences, State University of São Paulo, São Paulo, Brazil 3Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. 4Centro Técnico de Avaliação Genômica C.T.A.G, Ribeirão Preto, Brazil 5Itajaí City Hall, Itajaí, Brazil 6University of Toronto, Toronto, Canada, World Council for Health, Canadian Covid Care Alliance, 7Data Analysis, Universidad EAFIT, Cambridge, USA 8Front-Line Covid-19 Critical Care Alliance (FLCCC), USA 9Corpometria Institute, Brasilia, Brazil Corresponding author: Jennifer A. Hibberd, DDS, DPD, MRCDC Faculty of Dentistry, University of Toronto, Toronto, Ontario M5G 1X3 Canada [email protected] Keywords: COVID-19, SARS-CoV-2, rtPCR-SARS-CoV-2, ivermectin (IVM), prophylaxis, prevention, coronavirus Note: Terms & Dosages of Ivermectin IVM = 6mg/tablet Daily dosage = 0.2mg/kg/day = 1 tablet/30kg body weight Non-users, regular users, irregular users ..."
...AND NOW YOU ARE NO LONGER CLUELESS, ALTHOUGH YOU STILL ARE STILL AN ENIGMA...:-)
[ + ] xmasskull
[ - ] xmasskull 4 points 1.8 yearsJul 24, 2022 03:09:09 ago (+4/-0)
covid hoax,(((they)))just won't get off it!!
[ + ] Centaurus
[ - ] Centaurus 2 points 1.8 yearsJul 24, 2022 09:22:49 ago (+2/-0)
[ + ] 1Icemonkey
[ - ] 1Icemonkey 3 points 1.8 yearsJul 24, 2022 00:53:04 ago (+3/-0)
[ + ] MasklessTheGreat
[ - ] MasklessTheGreat 2 points 1.8 yearsJul 24, 2022 09:05:05 ago (+2/-0)
[ + ] 1Icemonkey
[ - ] 1Icemonkey 2 points 1.8 yearsJul 24, 2022 00:51:57 ago (+2/-0)
[ + ] beece
[ - ] beece [op] 0 points 1.8 yearsJul 24, 2022 09:04:18 ago (+0/-0)
[ + ] totes_magotes
[ - ] totes_magotes 1 point 1.8 yearsJul 24, 2022 09:51:49 ago (+1/-0)
Post the actual study.
[ + ] PostWallHelena
[ - ] PostWallHelena 1 point 1.8 yearsJul 24, 2022 08:07:01 ago (+1/-0)
I do not want him to get this shit. Not omicron or anything else. He’s too old. He’s like Joe Biden old.
So he still has not gotten covid. He has been exposed alot by less cautious family members. I still can’t believe it. I hope Im not jinxing it by writing this comment. I think it might be the ivermectin. It hasn’t really caused any problems except for mild diarrhea but that problem was solved with some probiotic yogurt. Im glad he’s not dead. Usually.
[ + ] Clueless_Enigma
[ - ] Clueless_Enigma 0 points 1.8 yearsJul 24, 2022 08:06:06 ago (+0/-0)
[ + ] beece
[ - ] beece [op] 0 points 1.8 yearsJul 24, 2022 08:59:10 ago (+0/-0)*
LOOKS LIKE THIS BELOW (THERES MORE THERE)
"Background: We have previously demonstrated that ivermectin used as prophylaxis for COVID-19, irrespective of the regularity or the level of monitoring, in a strictly controlled city-wide program in Southern Brazil (Itajaí, SC, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin showed an impact on the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect. Materials and methods: This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2mg/kg/day for two consecutive days, every 15 days. Data was gathered over a 150-day period. Regularity definitions were as follows: regular users had 180mg or more of ivermectin; irregular users had up to 60mg, in total, throughout the period of the program. Comparisons were made between non-users (subjects who did not use ivermectin), regular and irregular users from the city of Itajaí after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and risk of dying from COVID-19. The COVID-19 database was used, propensity score matching (PSM) was evened for intervals of age and comorbidities for hospitalization and mortality rates, and then adjusted for remaining variables (doubly adjusted). Risk of dying from COVID-19 was determined by the number of COVID-19 deaths in a certain population exposed to COVID-19. Results: Among 223,128 subjects analyzed from the city of Itajaí, 159,560 had 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8% of users) used irregularly (up to 60mg) and 8,325 (7.3%) used regularly (more than 180mg). The remaining 71,548 participants (62.9%) used intermediate dioses (between 60mg and 180mg) and were not included for analysis. A total of COVID-19 infection rate was 49% lower for regular users (3.40% rate) than non-users (6.64% rate) [risk rate (RR), 0.51; 95% confidence interval (95%CI), 0.45–0.58; p<0.0001], and 25% lower than irregular users (4.54% rate) (RR, 0.75; 95%CI, 0.66–0.85; p<0.0001]. The infection rate was 32% lower for irregular users than non-users (RR, 0.68; 95%CI, 0.64–0.73; p<0.0001). Among COVID-19 participants, regular users were older and had higher a prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, and between regular users and irregular users, and 1,542 subjects between non-users and irregular users. Hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p<0.0001 for both), and by 29% among irregular users compared to non-users (RR, 0.781; 95%CI, 0.49–1.05; p=0.099). Mortality rate was 92% lower in regular users than non-users (RR, 0.08; 95%CI, 0.02–0.35; p=0.0008) and 84% lower than irregular users (RR, 0.16; 95%CI, 0.04–0.71; p=0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR, 06.7; 95%CI, 0.40–0.99; p=0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR, 0.14; 95%CI, 0.03–0.57; p=0.006), and 72% lower than irregular users (RR, 0.28; 95%CI, 0.07–1.18; p=0.083), while irregular users had a 51% reduction compared to non-users (RR, 0.49; 95%CI, 0.32–0.76; p=0.001). Conclusion: Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin in a PSM comparison of a strictly controlled population. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19. NOTE: This is the new version of the manuscript that analyzed the efficacy of ivermectin according to the regularity of its use. Due to the substantial changes, a new page has been created.
ResearchGate Logo
Discover the world's research
20+ million members
135+ million publications
700k+ research projects
Join for free
Public Full-text 1
Content uploaded by Cadegiani Flávio
Author content
Content may be subject to copyright.
1 Regular use of ivermectin as prophylaxis for COVID-19 led up to 92% reduction in COVID-19 mortality rate in a dose-response manner: results of a prospective observational study of a strictly controlled population of 88,012 subjects among 223,128 participants. Lucy Kerr, MD, ARDMS1, Fernando Baldi, PhD2, Raysildo Barbosa Lôbo, PhD3, Washington Luiz Olivato Assagra4, Fernando Carlos Proença5, Jennifer A. Hibberd, DDS, DPD, MRCDC6, Juan J Chamie-Quintero7, Pierre Kory, MD, MPA8, Flavio A. Cadegiani, MD, MSc, PhD8,9 1Instituto Kerr, São Paulo, Brazil 2Department of Animal Sciences, State University of São Paulo, São Paulo, Brazil 3Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. 4Centro Técnico de Avaliação Genômica C.T.A.G, Ribeirão Preto, Brazil 5Itajaí City Hall, Itajaí, Brazil 6University of Toronto, Toronto, Canada, World Council for Health, Canadian Covid Care Alliance, 7Data Analysis, Universidad EAFIT, Cambridge, USA 8Front-Line Covid-19 Critical Care Alliance (FLCCC), USA 9Corpometria Institute, Brasilia, Brazil Corresponding author: Jennifer A. Hibberd, DDS, DPD, MRCDC Faculty of Dentistry, University of Toronto, Toronto, Ontario M5G 1X3 Canada [email protected] Keywords: COVID-19, SARS-CoV-2, rtPCR-SARS-CoV-2, ivermectin (IVM), prophylaxis, prevention, coronavirus Note: Terms & Dosages of Ivermectin IVM = 6mg/tablet Daily dosage = 0.2mg/kg/day = 1 tablet/30kg body weight Non-users, regular users, irregular users ..."
...AND NOW YOU ARE NO LONGER CLUELESS, ALTHOUGH YOU STILL ARE STILL AN ENIGMA...:-)